Numerai GP LLC Acquires New Shares in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Numerai GP LLC bought a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 6,821 shares of the company's stock, valued at approximately $2,820,000. IDEXX Laboratories makes up approximately 0.8% of Numerai GP LLC's portfolio, making the stock its 16th largest position.

Several other institutional investors have also recently added to or reduced their stakes in IDXX. United Capital Financial Advisors LLC boosted its holdings in shares of IDEXX Laboratories by 0.9% in the fourth quarter. United Capital Financial Advisors LLC now owns 2,446 shares of the company's stock valued at $1,011,000 after acquiring an additional 22 shares during the period. Cranbrook Wealth Management LLC increased its stake in IDEXX Laboratories by 7.0% in the fourth quarter. Cranbrook Wealth Management LLC now owns 382 shares of the company's stock valued at $158,000 after purchasing an additional 25 shares during the period. Gabelli Funds LLC increased its position in IDEXX Laboratories by 5.3% in the 4th quarter. Gabelli Funds LLC now owns 500 shares of the company's stock valued at $207,000 after acquiring an additional 25 shares during the period. Perigon Wealth Management LLC lifted its position in IDEXX Laboratories by 1.8% during the 4th quarter. Perigon Wealth Management LLC now owns 1,474 shares of the company's stock worth $632,000 after acquiring an additional 26 shares during the period. Finally, Summit Trail Advisors LLC raised its stake in shares of IDEXX Laboratories by 3.3% during the fourth quarter. Summit Trail Advisors LLC now owns 810 shares of the company's stock worth $335,000 after purchasing an additional 26 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Stock Down 0.1%

Shares of NASDAQ:IDXX traded down $0.32 during mid-day trading on Monday, hitting $517.78. 108,957 shares of the company traded hands, compared to its average volume of 647,605. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $545.43. The firm's 50 day simple moving average is $431.28 and its 200 day simple moving average is $431.45. The firm has a market cap of $41.64 billion, a P/E ratio of 48.47, a PEG ratio of 3.41 and a beta of 1.52.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.93 by $0.03. The firm had revenue of $998.43 million for the quarter, compared to analysts' expectations of $998.25 million. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The firm's quarterly revenue was up 3.6% on a year-over-year basis. During the same period in the prior year, the company posted $2.71 earnings per share. On average, equities analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently commented on IDXX shares. Bank of America raised their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 4th. StockNews.com raised IDEXX Laboratories from a "hold" rating to a "buy" rating in a report on Friday, May 9th. Stifel Nicolaus raised their price objective on shares of IDEXX Laboratories from $460.00 to $510.00 and gave the company a "hold" rating in a research note on Monday. Morgan Stanley increased their target price on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a report on Monday, May 5th. Finally, Barclays raised their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 4th. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $536.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.